Introduction: The 9-valent human papillomavirus (9vHPV) vaccine covers the same HPV
types (6/11/16/18) as the quadrivalent HPV (qHPV) vaccine and 5 additional cancer-causing …

ABSTRACT A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV
type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from …

The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection
causes> 550,000 cases of cervical and anogenital cancer worldwide annually. Infection also …

In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …

Human papillomavirus (HPV) related disease remains a major cause of morbidity and
mortality worldwide. Prophylactic vaccines have been recognized as the most effective …

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …

BACKGROUND: Human papillomaviruses (HPVs) play an obligatory role in cervical cancer
devel-opment. Thus, immunization of women using a prophylactic vaccine against the most …

An association between human papillomavirus (HPV) infection and the development of
cervical cancer was initially suggested over 30 years ago, and today there is clear evidence …

The risk for acquiring human papillomavirus (HPV) infections and associated diseases is
lifelong. An important part of prophylactic HPV vaccine development is durable protection …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …